Get the Stockscreener App
16.49
4.41%
-0.76
After Hours:
16.55
0.06
+0.36%
Staar Surgical Co stock is traded at $16.49, with a volume of 1.00M.
It is down -4.41% in the last 24 hours and down -25.08% over the past month.
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of its sales are generated from the ophthalmic surgical product segment.
See More
Previous Close:
$17.25
Open:
$17.21
24h Volume:
1.00M
Relative Volume:
0.73
Market Cap:
$814.04M
Revenue:
$224.45M
Net Income/Loss:
$-95.27M
P/E Ratio:
-8.544
EPS:
-1.93
Net Cash Flow:
$-43.74M
1W Performance:
-3.40%
1M Performance:
-25.08%
6M Performance:
-39.80%
1Y Performance:
+0.06%
1-Day Range:
$16.43
$17.23
1-Week Range:
$16.43
$17.73
52-Week Range:
$14.69
$30.81
Staar Surgical Co Stock (STAA) Company Profile
Name
Staar Surgical Co
Sector
Industry
Phone
(626) 303-7902
Address
1911 WALKER AVE, MONROVIA, CA
Compare STAA vs ISRG, BDX, ALC, MDLN, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
STAA
Staar Surgical Co
|
16.49 | 851.56M | 224.45M | -95.27M | -43.74M | -1.93 |
|
ISRG
Intuitive Surgical Inc
|
478.60 | 176.19B | 10.06B | 2.88B | 2.49B | 7.876 |
|
BDX
Becton Dickinson Co
|
177.81 | 51.41B | 21.92B | 1.76B | 2.63B | 6.1223 |
|
ALC
Alcon Inc
|
78.55 | 39.00B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
MDLN
Medline Inc
|
44.59 | 37.48B | 27.43B | 1.27B | 1.01B | 1.5829 |
|
RMD
Resmed Inc
|
245.73 | 37.82B | 5.40B | 1.49B | 1.78B | 10.12 |
Staar Surgical Co Stock (STAA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-03-26 | Initiated | Wedbush | Neutral |
| Jan-16-26 | Resumed | Morgan Stanley | Underweight |
| Apr-21-25 | Initiated | Wells Fargo | Equal Weight |
| Feb-12-25 | Downgrade | BTIG Research | Buy → Neutral |
| Feb-12-25 | Downgrade | Jefferies | Buy → Hold |
| Feb-12-25 | Downgrade | Mizuho | Outperform → Neutral |
| Feb-12-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-15-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jun-11-24 | Upgrade | BTIG Research | Neutral → Buy |
| Mar-11-24 | Upgrade | Stifel | Hold → Buy |
| Dec-05-23 | Downgrade | Needham | Buy → Hold |
| Dec-04-23 | Initiated | Morgan Stanley | Equal-Weight |
| Sep-15-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Aug-03-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Jun-07-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-17-23 | Initiated | Piper Sandler | Neutral |
| Feb-06-23 | Downgrade | BTIG Research | Buy → Neutral |
| Dec-28-22 | Reiterated | BTIG Research | Buy |
| Dec-08-22 | Initiated | Stifel | Hold |
| Nov-07-22 | Upgrade | Sidoti | Neutral → Buy |
| Oct-14-22 | Resumed | Stephens | Overweight |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Apr-08-22 | Initiated | Needham | Buy |
| Mar-28-22 | Upgrade | The Benchmark Company | Hold → Buy |
| Mar-18-22 | Upgrade | BTIG Research | Neutral → Buy |
| Jul-09-21 | Initiated | Oppenheimer | Perform |
| Jan-19-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Oct-26-20 | Downgrade | Sidoti | Buy → Neutral |
| Aug-31-20 | Upgrade | Sidoti | Neutral → Buy |
| Aug-06-20 | Reiterated | The Benchmark Company | Buy |
| Jul-06-20 | Downgrade | Sidoti | Buy → Neutral |
| Jun-24-20 | Downgrade | BTIG Research | Buy → Neutral |
| Jun-15-20 | Initiated | Jefferies | Buy |
| Dec-04-19 | Initiated | BTIG Research | Buy |
| Sep-24-18 | Reiterated | The Benchmark Company | Buy |
| Aug-06-18 | Resumed | The Benchmark Company | Buy |
| Nov-20-17 | Reiterated | The Benchmark Company | Buy |
| Aug-14-17 | Reiterated | The Benchmark Company | Buy |
| Mar-03-17 | Reiterated | The Benchmark Company | Buy |
| May-18-16 | Upgrade | The Benchmark Company | Hold → Buy |
| Sep-10-13 | Resumed | The Benchmark Company | Buy |
| Feb-28-13 | Reiterated | The Benchmark Company | Buy |
| Nov-01-12 | Downgrade | Canaccord Genuity | Buy → Hold |
| Mar-02-12 | Initiated | Northland Securities | Outperform |
| Oct-25-11 | Reiterated | The Benchmark Company | Buy |
| Oct-12-10 | Initiated | Morgan Joseph | Buy |
| May-11-10 | Initiated | Benchmark | Buy |
View All
Staar Surgical Co Stock (STAA) Latest News
Alpine Associates Management Inc. Acquires Shares of 913,087 STAAR Surgical Company $STAA - MarketBeat
VIEW Optometry launches to support independent practices - Eyes On Eyecare
STAAR Surgical Company (NASDAQ:STAA) Given Average Recommendation of "Reduce" by Analysts - MarketBeat
212,421 Shares in STAAR Surgical Company $STAA Acquired by Versor Investments LP - MarketBeat
Eli Lilly To Rally More Than 21%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga
STAAR Surgical (NASDAQ:STAA) Given New $19.00 Price Target at Stifel Nicolaus - MarketBeat
Staar Surgical price target lowered to $19 from $28 at Stifel - TipRanks
Leadership watch: Staar Surgical names co-CEOs, ACET adds to Board - Eyes On Eyecare
STAAR Surgical stock price target lowered to $19 by Stifel on China concerns By Investing.com - Investing.com India
STAAR Surgical stock price target lowered to $19 by Stifel on China concerns - Investing.com Nigeria
1 Cash-Heavy Stock on Our Watchlist and 2 We Brush Off - Finviz
Staar Surgical CoEnters agreement with Chief Legal Officer Nathaniel SisitskySEC filing - marketscreener.com
STAAR Surgical Company (STAA): A Bull Case Theory - Finviz
Staar Surgical initiated with a Neutral at Wedbush - TipRanks
STAAR Surgical sinks as it plans to terminate sale to Alcon (update) - MSN
Staar Surgical (STAA) to Report Q4 Results: Wall Street Expects Earnings Growth - Finviz
STAA Receives Neutral Rating as Wedbush Initiates Coverage | STA - GuruFocus
STAAR names interim co-CEOs amid search for permanent leader - MedTech Dive
STAAR Surgical (NASDAQ:STAA) Now Covered by Wedbush - MarketBeat
STAAR Surgical (STAA) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
STAAR Surgical Names Warren Foust and Deborah Andrews Interim Co-CEOs - VisionMonday.com
Why STAAR Surgical (STAA) stock is trading lower today - MSN
Staar Surgical names interim co-CEOs in leadership shift following failed Alcon deal - massdevice.com
Why STAAR Surgical (STAA) Shares Are Down Today - Bitget
Why STAAR Surgical (STAA) Stock Is Trading Lower Today - Finviz
Staar Surgical Appoints Interim Co-CEOs - Orange County Business Journal
STAAR Surgical Appoints Warren Foust and Deborah Andrews Interim Co-CEOs - PharmiWeb.com
New weekly contact lens offers Canadians 16 hours of daily comfort - stocktitan.net
Staar Surgical appoints Warren Foust & Deborah Andrews interim co-CEOs - marketscreener.com
STAAR Surgical Company Announces Interim Co-CEO Appointments, Effective February 1, 2026 - marketscreener.com
Staar Surgical (STAA) Appoints Interim Co-CEOs as CEO Search Beg - GuruFocus
A month after Alcon deal fell through, Staar Surgical searches for next CEO and names interim leaders - Fierce Biotech
Staar Surgical Names Interim Co-CEOs Amid Leadership Transition - TipRanks
Staar Surgical appoints COO Warren Foust, CFO Deborah Andrews as interim co-CEOs - TipRanks
STAAR Surgical Company (STAA) Stock Analysis: Insights Into The 23.34% Potential Upside - DirectorsTalk Interviews
Alcon Targets Faster Growth In 2026 With New Cataract Surgery Systems - Benzinga
Assessing Staar Surgical: Insights From 4 Financial Analysts - Benzinga
Jefferies Lowers Staar Surgical (STAA) Price Target to $21.50 | STAA Stock News - GuruFocus
Jefferies Lowers Staar Surgical (STAA) Price Target to $21.50 | - GuruFocus
Jefferies Financial Group Lowers STAAR Surgical (NASDAQ:STAA) Price Target to $21.50 - MarketBeat
Alcon announces purchase of STARR Surgical for $1.5 billion - MSN
The Truth About STAAR Surgical Co: The Tiny Eye Stock Chasing a Massive Glow-Up - AD HOC NEWS
Analysts Question STAAR Surgical Company (STAA)'s Post-Merger Standalone Valuation - Finviz
Analysts Question STAAR Surgical Company (STAA)’s Post-Merger Standalone Valuation - Insider Monkey
The Truth About STAAR Surgical Co: Is This Eye Tech Stock About To Blow Up Or Black Out? - AD HOC NEWS
Is STAAR Surgical (STAA) Attractively Priced After Prolonged Share Price Weakness? - simplywall.st
Staar Surgical, Dynatrace, and More Stocks See Action From Activist Investors -- Barrons.com - 富途牛牛
STAAR Surgical Company (STAA) Investor Outlook: Assessing The 21% Potential Upside - DirectorsTalk Interviews
Eye-care giant Alcon spends $750M buying back its own stock - Stock Titan
Staar Surgical Terminates $1.6B Sale to Alcon - Orange County Business Journal
Implantable Collamer Lens (ICL) Market to Reach USD 810 Million - openPR.com
Staar Surgical Co Stock (STAA) Financials Data
Revenue
Net Income
Cash Flow
EPS
6.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):